Table 4.

Safety overview of AEs

Number of subjects with at least one	Sandoz proposed biosimilar pegfilgrastim N = 176, n (%)	Reference pegfilgrastim N = 178, n (%)
TEAE	170 (97)	172 (97)
Study drug‐related AE	168 (95)	170 (96)
Study drug‐related TEAE leading to study drug discontinuation	1 (1)	1 (1)
Serious TEAE	0	0
AE occurring ≥4 weeks after the last IMP administration leading to study drug discontinuation	1 (1)	1 (1)

N, number of subjects in treatment group; n, number of subjects with event; TEAE, treatment‐emergent adverse event; AE, adverse event; IMP, investigational medicinal product